These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 24737875)

  • 1. Erythropoiesis-stimulating agent use after changes in medicare reimbursement policies.
    Hershman DL; Neugut AI; Shim JJ; Glied S; Tsai WY; Wright JD
    J Oncol Pract; 2014 Jul; 10(4):264-9. PubMed ID: 24737875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns of use and risks associated with erythropoiesis-stimulating agents among Medicare patients with cancer.
    Hershman DL; Buono DL; Malin J; McBride R; Tsai WY; Neugut AI
    J Natl Cancer Inst; 2009 Dec; 101(23):1633-41. PubMed ID: 19903808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in the use of erythropoiesis-stimulating agents (ESAs) and red blood cell transfusion in patients with cancer amidst regulatory and reimbursement changes.
    Gawade PL; Berlin JA; Henry DH; Tomita D; Brooks BD; Franklin J; Bradbury BD; Critchlow CW
    Pharmacoepidemiol Drug Saf; 2017 Nov; 26(11):1357-1366. PubMed ID: 28809079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Centers for Medicare & Medicaid Services national coverage determination on erythropoiesis-stimulating agent and transfusion use in chemotherapy-treated cancer patients.
    Arneson TJ; Li S; Gilbertson DT; Bridges KR; Acquavella JF; Collins AJ
    Pharmacoepidemiol Drug Saf; 2012 Aug; 21(8):857-64. PubMed ID: 22450901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Racial/ethnic and gender disparities in the use of erythropoiesis-stimulating agents and blood transfusions: cancer management under Medicare's reimbursement policy.
    Li M; Schulz R; Chisholm-Burns M; Wang J; Lu ZK
    J Manag Care Spec Pharm; 2020 Nov; 26(11):1477-1486. PubMed ID: 33119441
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical and economic outcomes in Medicare beneficiaries with stage 3 or stage 4 chronic kidney disease and anemia: the role of intravenous iron therapy.
    Knight TG; Ryan K; Schaefer CP; D'Sylva L; Durden ED
    J Manag Care Pharm; 2010 Oct; 16(8):605-15. PubMed ID: 20866165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physician characteristics and variability of erythropoiesis-stimulating agent use among Medicare patients with cancer.
    Wright JD; Neugut AI; Wilde ET; Buono DL; Malin J; Tsai WY; Hershman DL
    J Clin Oncol; 2011 Sep; 29(25):3408-18. PubMed ID: 21810679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transfusions increase with nationally driven reimbursement changes of erythropoiesis stimulating agents for chemotherapy-induced anemia.
    Yu JM; Shord SS; Cuellar S
    J Oncol Pharm Pract; 2011 Dec; 17(4):360-5. PubMed ID: 20826550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association Between Changes in CMS Reimbursement Policy and Drug Labels for Erythrocyte-Stimulating Agents With Outcomes for Older Patients Undergoing Hemodialysis Covered by Fee-for-Service Medicare.
    Wang C; Kane R; Levenson M; Kelman J; Wernecke M; Lee JY; Kozlowski S; Dekmezian C; Zhang Z; Thompson A; Smith K; Wu YT; Wei Y; Chillarige Y; Ryan Q; Worrall C; MaCurdy TE; Graham DJ
    JAMA Intern Med; 2016 Dec; 176(12):1818-1825. PubMed ID: 27775769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug utilisation and cost considerations of erythropoiesis stimulating agents in oncology patients receiving chemotherapy: observations from a large managed-care database.
    Vekeman F; McKenzie RS; Bookhart BK; Laliberté F; Duh MS; Tak Piech C; Lefebvre P
    J Med Econ; 2009 Mar; 12(1):1-8. PubMed ID: 19450059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical costs and associated racial/ethnic and sex disparities in erythropoiesis-stimulating agent use: anemia management under the Medicare reimbursement policy.
    Li M; Cai B; Mauldin P; Lu ZK
    J Manag Care Spec Pharm; 2021 Aug; 27(8):1142-1152. PubMed ID: 34337992
    [No Abstract]   [Full Text] [Related]  

  • 12. Red blood cell (RBC) transfusion rates among US chronic dialysis patients during changes to Medicare end-stage renal disease (ESRD) reimbursement systems and erythropoiesis stimulating agent (ESA) labels.
    Cappell KA; Shreay S; Cao Z; Varker HV; Paoli CJ; Gitlin M
    BMC Nephrol; 2014 Jul; 15():116. PubMed ID: 25015348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of reimbursement changes on erythropoiesis-stimulating agent utilization and transfusions.
    Hess G; Nordyke RJ; Hill J; Hulnick S
    Am J Hematol; 2010 Nov; 85(11):838-43. PubMed ID: 20976794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of changes in reimbursement policies and institutional practice algorithm for utilization of erythropoietic-stimulating agents on treatment patterns and costs in anemic lymphoma patients.
    Lal LS; Raju A; Miller LA; Chen H; Arbuckle R; Sansgiry SS
    Support Care Cancer; 2010 Feb; 19(2):251-9. PubMed ID: 20101414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erythropoiesis stimulating agents and clinical outcomes of invasive breast cancer patients receiving cytotoxic chemotherapy.
    Lai Y; Palazzo JP; Cristofanilli M; Hyslop T; Civan J; Avery T; Myers RE; Li B; Ye Z; Xing J; Yang H
    Breast Cancer Res Treat; 2014 Nov; 148(1):175-85. PubMed ID: 25261294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of erythropoiesis-stimulating agents on the short-term and long-term survivals in metastatic breast cancer patients receiving chemotherapy: a SEER population-based study.
    Lai Y; Ye Z; Civan JM; Wang C; Cristofanilli M; Mu Z; Austin L; Palazzo JP; Myers RE; Yang H
    Breast Cancer Res Treat; 2015 Sep; 153(2):407-16. PubMed ID: 26264468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of the US Food and Drug Administration Boxed Warning of Erythropoietin-Stimulating Agents on Utilization and Adverse Outcome.
    Bian J; Chen B; Hershman DL; Marks N; Norris L; Schulz R; Bennett CL
    J Clin Oncol; 2017 Jun; 35(17):1945-1951. PubMed ID: 28441110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk evaluation mitigation strategy: impact of application of the Food and Drug Adminstration's strategy on use of erythropoiesis-stimulating agents and transfusion in patients with chemotherapy-induced anaemia.
    Hollingsworth K; Romney MC; Crawford A; McAna J
    J Clin Pharm Ther; 2015 Jun; 40(3):299-303. PubMed ID: 25893427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. End of an era of administering erythropoiesis stimulating agents among Veterans Administration cancer patients with chemotherapy-induced anemia.
    Hoque S; Chen BJ; Schoen MW; Carson KR; Keller J; Witherspoon BJ; Knopf KB; Yang YT; Schooley B; Nabhan C; Sartor O; Yarnold PR; Ray P; Bobolts L; Hrushesky WJ; Dickson M; Bennett CL
    PLoS One; 2020; 15(6):e0234541. PubMed ID: 32584835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. On-label and off-label prescribing patterns of erythropoiesis-stimulating agents in inpatient hospital settings in the US during the period of major regulatory changes.
    Seetasith A; Holdford D; Shah A; Patterson J
    Res Social Adm Pharm; 2017; 13(4):778-788. PubMed ID: 27595426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.